Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK3 | P49761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178753 | 1.00 | HSD17B10 (0.46) | HSD17B10NTRK1MAPK13MAPK12MAPK11 | |
| SCHEMBL3037462 | 0.77 | PLK1 (0.43) | CDK2CDK5DYRK3CCNT1CCNA2 | |
| SCHEMBL16468560 | 0.75 | PLK1 (0.45) | PLK1 | |
| SCHEMBL3040935 | 0.73 | FYN (0.65) | FYNCDK2CDK5DYRK3CCNT1 | |
| SCHEMBL3033366 | 0.73 | ALDH1A1 (0.46) | PLK1HTT | |
| SCHEMBL3039694 | 0.73 | FYN (0.65) | FYNCDK2CDK5DYRK3CCNT1 | |
| SCHEMBL9905636 | 0.71 | FYN (0.46) | NTRK1FYNCDK2CDK5DYRK3 | |
| SCHEMBL8512932 | 0.71 | FYN (0.46) | NTRK1FYNCDK2CDK5DYRK3 | |
| SCHEMBL16622975 | 0.70 | FYN (0.65) | FYNPLK1 | |
| SCHEMBL9905676 | 0.70 | FYN (0.46) | NTRK1FYNCDK2CDK5DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | HSD17B10 3781/4885NTRK1 445/4885MAPK13 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.